ECSP099482A - Preparación farmacéutica para reducir la endometriosis - Google Patents
Preparación farmacéutica para reducir la endometriosisInfo
- Publication number
- ECSP099482A ECSP099482A EC2009009482A ECSP099482A ECSP099482A EC SP099482 A ECSP099482 A EC SP099482A EC 2009009482 A EC2009009482 A EC 2009009482A EC SP099482 A ECSP099482 A EC SP099482A EC SP099482 A ECSP099482 A EC SP099482A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- endometriosis
- negative influence
- bone density
- pharmaceutical preparation
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000037182 bone density Effects 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010003497 Asphyxia Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 abstract 1
- 229960000978 cyproterone acetate Drugs 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica para el tratamiento de endometriosis sin reducir la densidad ósea contiene un gestágeno con eficacia antiandrogénica, con preferencia 17a-cianometil-l7-ß-hidroxiestra-4,9-dien-3-ona (dienogest), acetato de ciproterona o acetato de cloromadinona en una dosis diaria que es como máximo el doble de la dosis inhibidora de la ovulación, junto con uno o varios excipientes/portadores farmacéuticamente aceptables. La composición farmacéutica según la invención produce tanto la reducción de la endometriosis como también la ausencia de influencia negativa sobre el metabolismo óseo y de la densidad ósea y al mismo tiempo puede mantener en una medida tolerable los efectos colaterales conocidos de los medicamentos convencionales (por ejemplo, sofocaciones, acné, influencia negativa del perfil lipídico). La composición farmacéutica es por ello apropiada para la aplicación a largo plazo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07004202A EP1977752A1 (de) | 2007-03-01 | 2007-03-01 | Pharmazeutische Zubereitung zur Verminderung der Endometriose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099482A true ECSP099482A (es) | 2009-08-28 |
Family
ID=38045772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009482A ECSP099482A (es) | 2007-03-01 | 2009-07-03 | Preparación farmacéutica para reducir la endometriosis |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1977752A1 (es) |
| JP (1) | JP2010520159A (es) |
| KR (1) | KR20090119829A (es) |
| CN (1) | CN101583364A (es) |
| AU (1) | AU2008221012A1 (es) |
| BR (1) | BRPI0806598A2 (es) |
| CA (1) | CA2673936A1 (es) |
| CO (1) | CO6190606A2 (es) |
| CR (1) | CR10912A (es) |
| DO (1) | DOP2009000171A (es) |
| EA (1) | EA200900829A1 (es) |
| EC (1) | ECSP099482A (es) |
| MA (1) | MA31162B1 (es) |
| MX (1) | MX2009007259A (es) |
| NZ (1) | NZ577761A (es) |
| SV (1) | SV2009003324A (es) |
| TN (1) | TN2009000263A1 (es) |
| WO (1) | WO2008104342A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874806A (zh) * | 2009-04-29 | 2010-11-03 | 北京本草天源药物研究院 | 一种地诺孕素固体制剂 |
| CN102670519B (zh) * | 2011-03-16 | 2014-06-11 | 重庆莱美药业股份有限公司 | 一种可快速溶出的地诺孕素口服制剂及其制备方法 |
| CN103304619B (zh) * | 2013-06-08 | 2015-12-02 | 西藏海思科药业集团股份有限公司 | 一种地诺孕素化合物 |
| TW202523334A (zh) * | 2023-12-13 | 2025-06-16 | 大陸商長春金賽藥業有限責任公司 | 原位皮下植入的女性激素調節組合物及其製備方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| EP1655031A1 (de) * | 2004-10-08 | 2006-05-10 | Schering AG | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung |
-
2007
- 2007-03-01 EP EP07004202A patent/EP1977752A1/de not_active Withdrawn
-
2008
- 2008-02-23 JP JP2009551120A patent/JP2010520159A/ja active Pending
- 2008-02-23 AU AU2008221012A patent/AU2008221012A1/en not_active Abandoned
- 2008-02-23 KR KR1020097014169A patent/KR20090119829A/ko not_active Withdrawn
- 2008-02-23 EA EA200900829A patent/EA200900829A1/ru unknown
- 2008-02-23 EP EP08707797A patent/EP2059248A1/de not_active Ceased
- 2008-02-23 NZ NZ577761A patent/NZ577761A/en not_active IP Right Cessation
- 2008-02-23 CN CNA2008800023330A patent/CN101583364A/zh active Pending
- 2008-02-23 CA CA002673936A patent/CA2673936A1/en not_active Abandoned
- 2008-02-23 BR BRPI0806598-5A patent/BRPI0806598A2/pt not_active IP Right Cessation
- 2008-02-23 MX MX2009007259A patent/MX2009007259A/es unknown
- 2008-02-23 WO PCT/EP2008/001451 patent/WO2008104342A1/de not_active Ceased
-
2009
- 2009-06-24 TN TNP2009000263A patent/TN2009000263A1/fr unknown
- 2009-07-03 CO CO09068629A patent/CO6190606A2/es not_active Application Discontinuation
- 2009-07-03 DO DO2009000171A patent/DOP2009000171A/es unknown
- 2009-07-03 CR CR10912A patent/CR10912A/es unknown
- 2009-07-03 EC EC2009009482A patent/ECSP099482A/es unknown
- 2009-07-03 SV SV2009003324A patent/SV2009003324A/es not_active Application Discontinuation
- 2009-08-04 MA MA32138A patent/MA31162B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1977752A1 (de) | 2008-10-08 |
| CA2673936A1 (en) | 2008-09-04 |
| CN101583364A (zh) | 2009-11-18 |
| MX2009007259A (es) | 2009-07-10 |
| DOP2009000171A (es) | 2009-08-31 |
| CO6190606A2 (es) | 2010-08-19 |
| SV2009003324A (es) | 2009-10-02 |
| EA200900829A1 (ru) | 2010-02-26 |
| TN2009000263A1 (en) | 2010-10-18 |
| MA31162B1 (fr) | 2010-02-01 |
| JP2010520159A (ja) | 2010-06-10 |
| KR20090119829A (ko) | 2009-11-20 |
| AU2008221012A1 (en) | 2008-09-04 |
| WO2008104342A1 (de) | 2008-09-04 |
| CR10912A (es) | 2009-08-13 |
| EP2059248A1 (de) | 2009-05-20 |
| NZ577761A (en) | 2012-03-30 |
| BRPI0806598A2 (pt) | 2014-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
| MX2009010289A (es) | Composiciones para administracion nasal. | |
| UY33343A (es) | Formas de dosificación sólidas orales con dosis muy bajas para la hrt | |
| CL2011003291A1 (es) | Composicion farmaceutica de dosis unica que contiene a) como gestageno 50-90 µg de levonorgestrel y b) como inhibidor cox (ciclooxigenasa) 5-60 mg de piroxicam, 50-600 mg de indometacina o 40-450 mg de diclofenaco; y su uso para preparar medicamentos para la anticoncepcion en caso de emergencia. | |
| NO20091954L (no) | Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido | |
| CO6251259A2 (es) | Formulaciones farmaceuticas de estriol en baja dosis | |
| MX2012003551A (es) | Tabletas transformables via oral. | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| AR061959A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
| ECSP099482A (es) | Preparación farmacéutica para reducir la endometriosis | |
| UY32650A (es) | Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas | |
| CO2019000604A2 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d | |
| GT200900296A (es) | Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante. | |
| CU20090116A7 (es) | Preparación farmacéutica para reducir la endometriosis | |
| CU20110070A6 (es) | Método para tratar la endometriosis sin disminuir la densidad ósea | |
| MX2009008813A (es) | Composicion farmaceutica que contiene floroglucinol y paracetamol. | |
| AR080541A1 (es) | Tratamiento para la endometriosis | |
| AR053546A1 (es) | Forma farmacologica peroral solida para la anticoncepcion | |
| AR070023A1 (es) | Uso de gestagenos en combinacion con (6s)-5-metil-tetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo | |
| AR116592A1 (es) | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib | |
| DOP2007000122A (es) | Forma farmacologica peroral para anticoncepcion | |
| DOP2006000035A (es) | Preparación farmaceútica para la anticoncepción oral |